Rationale and design of the PHOspholamban RELated CARdiomyopathy intervention STudy (i-PHORECAST)

W. P. te Rijdt · E. T. Hoorntje · R. de Brouwer · A. Oomen · A. Amin · J. F. van der Heijden · J. C. Karper · B. D. Westenbrink · H. H. W. Sillijé · A. S. J. M. te Riele · A. C. P. Wiesfeld · I. C. van Gelder · T. P. Willems · P. A. van der Zwaag · J. P. van Tintelen · J. H. Hillege · H. L. Tan · D. J. van Veldhuisen · F. W. Asselbergs · R. A. de Boer · A. A. M. Wilde · M. P. van den Berg

Abstract
Background The p.Arg14del (c.40_42delAGA) phospholamban (PLN) pathogenic variant is a founder mutation that causes dilated cardiomyopathy (DCM) and arrhythmogenic cardiomyopathy (ACM). Carriers are at increased risk of malignant ventricular arrhythmias and heart failure, which has been ascribed to cardiac fibrosis. Importantly, cardiac fibrosis appears to be an early feature of the disease, occurring in many presymptomatic carriers before the onset of overt disease. As with most monogenic cardiomyopathies, no evidence-based treatment is available for presymptomatic carriers.

Aims The PHOspholamban RELated CARdiomyopathy intervention STudy (i-PHORECAST) is designed to demonstrate that pre-emptive treatment of presymptomatic PLN p.Arg14del carriers using eplerenone, a mineralocorticoid receptor antagonist with established antifibrotic effects, can reduce disease progression and postpone the onset of overt disease.

Methods iPHORECAST has a multicentre, prospective, randomised, open-label, blinded endpoint (PROBE) design. Presymptomatic PLN p.Arg14del carriers are randomised to receive either 50 mg eplerenone once daily or no treatment. The primary endpoint of the study is a multiparametric assessment of disease progression including cardiac magnetic resonance parameters (left and right ventricular volumes, systolic function and fibrosis), electrocardiographic parameters (QRS voltage, ventricular ectopy), signs and/or symptoms related to DCM and ACM, and cardiovascular death. The follow-up duration is set at 3 years.

Baseline results A total of 84 presymptomatic PLN p.Arg14del carriers (n=42 per group) were included.

J. F. van der Heijden · A. S. J. M. te Riele · F. W. Asselbergs
Department of Cardiology, Division Heart & Lungs, Utrecht UMC, Utrecht, The Netherlands

T. P. Willems
Department of Radiology, University of Groningen, Groningen UMC, Groningen, The Netherlands

J. P. van Tintelen
Department of Genetics, University of Utrecht, Utrecht UMC, Utrecht, The Netherlands

F. W. Asselbergs
Institute of Cardiovascular Science and Institute of Health Informatics, Faculty of Population Health Sciences, University College London, London, UK
Fig. 1 Function of phospholamban. Phospholamban (PLN; blue arrow) is a reversibly phosphorylated transmembrane protein that binds to and regulates the activity of the sarcoplasmic reticulum Ca^{2+} ATPase (SERCA2a) pump. *From:* MacLennan et al. Nat Rev Mol Cell Biol. 2003 [27]. Printed with permission from Springer Nature.

By design, at baseline, all participants were in New York Heart Association (NYHA) class I and had a left ventricular ejection fraction >45% and <2500 ventricular premature contractions during 24-hour Holter monitoring. There were no statistically significant differences between the two groups in any of the baseline characteristics. The study is currently well underway, with the last participants expected to finish in 2021.

**Conclusion** iPHORECAST is a multicentre, prospective randomised controlled trial designed to address whether pre-emptive treatment of PLN p.Arg14del carriers with eplerenone can prevent or delay the onset of cardiomyopathy. iPHORECAST has been registered in the clinicaltrials.gov-register (number: NCT01857856).

**Keywords** Cardiomyopathy · Intervention study · Phospholamban · Design · Pre-emptive treatment · Presymptomatic carriers

**Introduction**

In the Netherlands, approximately 15% of idiopathic dilated cardiomyopathy (DCM) patients and approximately 12% of arrhythmogenic right ventricular cardiomyopathy (ARVC) patients carry a single pathogenic variant, p.Arg14del (c.40_42delAGA), in the PLN gene that encodes the phospholamban protein, a regulator of cardiomyocyte calcium cycling (Fig. 1; [1]). The estimated prevalence of this founder mutation is approximately 1:500–1000 in large parts of the Netherlands. Moreover, it has been identified in several other European countries (Germany, Greece, Belgium, Norway, the UK and Spain), and in China, Canada and the United States of America, attesting to its global significance [2].

The clinical phenotype of PLN p.Arg14del carriers is characterised by malignant ventricular arrhythmias, sudden cardiac arrest and progressive heart failure [1, 3–5]. An experimental murine overexpression model of this PLN pathogenic variant found the cardiomyopathy to be characterised by progressive cardiomyocyte loss and severe cardiac fibrosis, and a similar phenotype was observed in a recently developed knock-in model that also recapitulated the clinical findings [6, 7]. Indeed, in our patients, we observed left ventricular myocardial fibrosis even in the presence of preserved (>45%) left ventricular ejection fraction (LVEF), which suggests that tissue remodelling occurs early on in PLN p.Arg14del carriers, occurring even before onset of overt disease [1, 8, 9]. An earlier study by our group showed that an LVEF below 45% (rather than 35%, as in other types of cardiomyopathy) is an independent risk factor for ventricular arrhythmia in PLN p.Arg14del carriers [3]. We recently refined this observation, showing that left ventricular late gadolinium enhancement (LV-LGE) is an even stronger risk factor than LVEF. In fact, even when LVEF is preserved, LV-LGE appeared to be associated with a higher risk of ventricular arrhythmia in PLN p.Arg14del carriers [9].

Analogous to other inherited cardiomyopathies, the natural course of PLN p.Arg14del cardiomyopathy is age-related; after a presymptomatic phase of variable
length, many PLN p.Arg14del carriers progress to overt cardiomyopathy. These patients are treated according to general clinical guidelines for these conditions.

Family cascade screening can, however, identify presymptomatic family members carrying the PLN p.Arg14del pathogenic variant, thereby providing a unique window of opportunity to initiate preemptive treatment in carriers before symptoms occur, potentially preventing sudden cardiac death or disease development and progression. However, no evidence-based treatment is currently available for presymptomatic carriers even though early treatment before the onset of any symptoms is potentially of major prognostic importance.

We reasoned that eplerenone, a selective mineralocorticoid receptor antagonist (MRA) with potent antifibrotic properties [10–16], might be effective as an early treatment for PLN p.Arg14del carriers. We are conducting the iPHORECAST trial to investigate whether treatment with eplerenone in presymptomatic PLN p.Arg14del carriers prevents or delays disease onset and symptoms.

### Study design

#### Objectives

The objective of the iPHORECAST trial is to show that eplerenone treatment can prevent or reduce progression of disease in presymptomatic PLN p.Arg14del carriers.

#### Study population

Specific inclusion and exclusion criteria are listed in Tab. 1. Previously, all known PLN p.Arg14del carriers in the Netherlands, including all presymptomatic carriers, were registered in the PHORECAST registry (PHOspholamban RELated Cardiomyopathy Study; http://www.phorecast.nl). Recently, all carriers have been incorporated in the national arrhythmogenic cardiomyopathy (ACM) registry (www.acmregistry.nl) [17]. We used the PHORECAST registry to recruit eligible presymptomatic subjects. Study participants are between 18 and 65 years of age, have a New York Heart Association (NYHA) functional class of 1 and an LVEF greater than 45% (as measured by cardiac magnetic resonance [CMR]). For ARVC and DCM criteria, we used the revised task force and Mestroni criteria respectively [18, 19]. Carriers taking other cardiovascular medication, including diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, beta-blockers and anti-arrhythmic medication, were excluded.

### Table 1  Key inclusion and exclusion criteria

| Key inclusion criteria                                                                 | Key exclusion criteria                                                                 |
|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| PLN p.Arg14del carriers                                                                 | Subjects unable or unwilling to provide written informed consent                      |
| Age ≥ 18 and ≤ 65 years                                                                  | Note: presence of late gadolinium enhancement on CMR is not an exclusion criterion     |
| New York Heart Association functional class ≤ 1                                          | Evidence of ischaemic heart disease                                                   |
| LV ejection fraction ≥ 45 (measured with MRI)                                             | Treatment with cardioactive medication                                                |
| Global or regional RV dysfunction and/or structural alterations (according to task force criterion 1 [18]) | Hyperkalaemia (serum potassium > 5.0 mmol/l)                                           |
| Ventricular premature complexes > 2500 during 24-hour Holter monitoring                  | Severe renal dysfunction (eGFR < 30 ml/min/1.73 m²)                                     |
| Non-sustained ventricular tachycardia during Holter monitoring                            | Severe hepatic impairment (Child-Pugh class C)                                        |
| History of sustained ventricular tachycardia or ventricular fibrillation                  | Women who are currently pregnant or report a recent pregnancy (last 60 days) or plan on becoming pregnant |
| Hypertension requiring the use of antihypertensive drugs, or when this is anticipated within the coming 3 years | Concomitant use of CYP3A4 inhibitors                                                  |
| Evidence of ischaemic heart disease                                                      | Concomitant use of NSAIDs                                                             |
| PLN p.Arg14del carriers                                                                  | Concomitant use of potassium-sparing agents                                           |
| New York Heart Association functional class ≤ 1                                          | Known intolerance or contraindication for aldosterone antagonists                      |
| LV ejection fraction ≥ 45 (measured with MRI)                                             | Participation in another drug trial in which the last dose of drug was within the past 30 days |
| Global or regional RV dysfunction and/or structural alterations (according to task force criterion 1 [18]) | Contra-indications for CMR (claustrophobia, metal devices)                           |
| A diagnosis of DCM (according to the Mestroni criteria [19])                             | Subjects unable or unwilling to provide written informed consent                      |
| A diagnosis of ARVC (according to the task force criteria [18])                           | Note: presence of late gadolinium enhancement on CMR is not an exclusion criterion     |
| Ventricular premature complexes > 2500 during 24-hour Holter monitoring                  | Evidence of ischaemic heart disease                                                   |
| Non-sustained ventricular tachycardia during Holter monitoring                            | Treatment with cardioactive medication                                                |
| Hypertension requiring the use of antihypertensive drugs, or when this is anticipated within the coming 3 years | Hyperkalaemia (serum potassium > 5.0 mmol/l)                                           |
| Evidence of ischaemic heart disease                                                      | Severe renal dysfunction (eGFR < 30 ml/min/1.73 m²)                                     |
| Evidence of ischaemic heart disease                                                      | Severe hepatic impairment (Child-Pugh class C)                                        |
| PLN p.Arg14del carriers                                                                  | Women who are currently pregnant or report a recent pregnancy (last 60 days) or plan on becoming pregnant |
| New York Heart Association functional class ≤ 1                                          | Concomitant use of CYP3A4 inhibitors                                                  |
| LV ejection fraction ≥ 45 (measured with MRI)                                             | Concomitant use of NSAIDs                                                             |
| Global or regional RV dysfunction and/or structural alterations (according to task force criterion 1 [18]) | Concomitant use of potassium-sparing agents                                           |
| A diagnosis of DCM (according to the Mestroni criteria [19])                             | Known intolerance or contraindication for aldosterone antagonists                      |
| Ventricular premature complexes > 2500 during 24-hour Holter monitoring                  | Participation in another drug trial in which the last dose of drug was within the past 30 days |
| Non-sustained ventricular tachycardia during Holter monitoring                            | Contra-indications for CMR (claustrophobia, metal devices)                           |
| Hypertension requiring the use of antihypertensive drugs, or when this is anticipated within the coming 3 years | Subjects unable or unwilling to provide written informed consent                      |
| Evidence of ischaemic heart disease                                                      | Note: presence of late gadolinium enhancement on CMR is not an exclusion criterion     |
| Treatment with cardioactive medication                                                    | Evidence of ischaemic heart disease                                                   |
| Hyperkalaemia (serum potassium > 5.0 mmol/l)                                             | Treatment with cardioactive medication                                                |
| Severe renal dysfunction (eGFR < 30 ml/min/1.73 m²)                                       | Hyperkalaemia (serum potassium > 5.0 mmol/l)                                           |
| Severe hepatic impairment (Child-Pugh class C)                                          | Severe renal dysfunction (eGFR < 30 ml/min/1.73 m²)                                     |
| Women who are currently pregnant or report a recent pregnancy (last 60 days) or plan on becoming pregnant | Severe hepatic impairment (Child-Pugh class C)                                        |
| Concomitant use of CYP3A4 inhibitors                                                     | Women who are currently pregnant or report a recent pregnancy (last 60 days) or plan on becoming pregnant |
| Concomitant use of NSAIDs                                                                | Concomitant use of potassium-sparing agents                                           |
| Concomitant use of potassium-sparing agents                                              | Known intolerance or contraindication for aldosterone antagonists                      |
| Participation in another drug trial in which the last dose of drug was within the past 30 days | Participation in another drug trial in which the last dose of drug was within the past 30 days |
| Contra-indications for CMR (claustrophobia, metal devices)                               | Note: presence of late gadolinium enhancement on CMR is not an exclusion criterion     |
| Subjects unable or unwilling to provide written informed consent                        | Evidence of ischaemic heart disease                                                   |

### Design

This outpatient study is a multicentre, prospective, randomised trial with blinded assessment of endpoints design (PROBE) [20]. The participating centres are the University Medical Center Groningen (which is the coordinating centre and CMR core lab); Amsterdam University Medical Center; Antonius Hospital Sneek and University Medical Center Utrecht. Carriers were randomly assigned to one of the two study arms, either eplerenone or control (no treatment), in a 1:1 ratio. The follow-up period is 3 years (see the section Study endpoints).
Ethical considerations

This study is conducted in accordance with the principles stated in the revised Declaration of Helsinki (Seoul 2008) and in accordance with the Medical Research Involving Human Subjects Act. The medical ethics committee of the University Medical Center Groningen, the Netherlands, approved this study (METc 2013-272; ABR NL43771.042.13; EudraCT 2013-001067-23). The study protocol was also submitted to and approved by the medical ethics committee of each participating hospital. Written informed consent was obtained from every subject before entry into the study. An independent data and safety monitoring board (DSMB) safeguards the interests of i-PHORECAST trial participants, assesses the safety of the interventions during the trial and monitors the overall conduct of the clinical trial. The study has been registered and kept up-to-date in the clinicaltrials.gov-register (number: NCT01857856).

Treatment

In the treatment arm, eplerenone was initiated on the day of randomisation at 50 mg orally once daily. The dose of 50 mg once daily is the recommended dose in patients with heart failure. Carriers are maintained at this target dose, or the maximum tolerated dose, until the end of the study. Serum potassium and estimated glomerular filtration rate (eGRF) are monitored at the start of the study, 1–2 week(s) after study start and yearly, and these measures are documented together with the other investigations and vital parameters. The dose is reduced if needed, i.e. in case of hyperkalaemia (serum potassium > 5.5 mmol/l). Carriers undergo yearly follow-up in the cardiology outpatient clinic at each participating centre following routine clinical care. Physical examination, blood sampling (when treated with eplerenone), electrocardiogram, Holter monitoring and ergometry are performed every 12 months. CMR imaging and SA-ECG are performed at the start and end (36 months) of the study (Tab. 2).

Study endpoints

The primary and secondary endpoints are listed in Tab. 3. The primary endpoint is a multiparametric assessment of disease progression defined as a responder-based composite primary endpoint (Table 3). If one of the predefined parameters of the composite primary endpoint is reached, CMR imaging is performed and study end date recorded. After a follow-up period of 3 years, outcomes will be assessed by an independent adjudication committee blinded to the allocated group. In case of a favourable trend (but no

Table 2 Overview of study procedures

| Visit | Visit 1 start | Visit 2 1 week | Visit 3 1 year | Visit 4 2 years | Visit 5 3 years |
|-------|--------------|----------------|---------------|----------------|----------------|
| Visit to outpatient clinic | ✔ | – | ✔ | ✔ | ✔ |
| History and current status | – | ✔ | ✔ | ✔ | ✔ |
| Physical examination | ✔ | – | ✔ | ✔ | ✔ |
| Electrocardiogram | – | ✔ | ✔ | ✔ | ✔ |
| Echocardiogram | – | – | ✔ | ✔ | ✔ |
| Holter monitoring | – | – | ✔ | ✔ | ✔ |
| Ergometry | – | – | ✔ | ✔ | ✔ |
| Signal-averaged ECG | ✔ | – | – | – | – |
| CMR | ✔ | – | – | – | ✔ |
| Blood analysis | ✔ | ✔ | ✔ | ✔ | ✔ |

Note: Subjects undergo several investigations as summarised in this table. They are requested to visit the outpatient clinic at baseline and at 1-year intervals thereafter. Subjects randomised to eplerenone visit the outpatient clinic or their general practitioner after 1 week to check serum potassium and eGRF, which are also checked in these subjects at the yearly visits. Of note, all investigations except blood analysis are already performed as part of routine clinical care, which routinely includes evaluation of signs and symptoms of DCM and ACM. For the purpose of the study, we collect and use these available data.

Table 3 Primary and secondary endpoints

**Primary endpoint**
- LV end-diastolic volume, increase > 10% (assessed with CMR)
- LV ejection fraction, absolute decrease > 5% (assessed with CMR)
- RV end-diastolic volume, increase > 10% (assessed with CMR)
- RV ejection fraction, absolute decrease > 5% (assessed with CMR)
- Late enhancement, absolute increase > 5% (assessed with CMR)
- QRS voltage, decrease > 25% (ECG, measured in I, II and III in mV)
- Occurrence of non-sustained ventricular tachycardia (Holter monitoring, exercise testing)
- Heart failure signs and/or symptoms or arrhythmias necessitating medical treatment according to the guidelines and likely due to arrhythmogenic cardiomyopathy

**Secondary endpoints**
- All individual components of the primary endpoint
- Diagnosis of DCM (according to Mestroni criteria [19])
- Diagnosis of ARVC (according to revised task force criteria [18])
- Development of global or regional dysfunction and structural alterations (according to revised task force criterion 1 [18])
- QRS axis (12-lead ECG)
- Conduction intervals (PR interval, QRS duration [12-lead ECG; SA-ECG])
- STT segment changes (12-lead ECG)
- Change in biomarkers
- Occurrence of sustained ventricular tachycardia or ventricular fibrillation
- Hospitalisation for a cardiovascular reason
- LV/left ventricular, CM/R/cardiomyopathy, eGFR estimated glomerular filtration rate, DCM dilated cardiomyopathy, ACM arrhythmogenic cardiomyopathy

* Only for subjects randomised to eplerenone
significant effect as yet), the DSMB may advise continuing the study for 2 more years ("adaptive design").

Sample size estimation

This clinical trial was designed based on the assumptions that 50% of the presymptomatic PLN p.Arg14del carrier group without treatment will reach the primary endpoint within 3 years and that treatment with eplerenone is expected to reduce this percentage by 50%. To ensure at least 80% power to detect a difference between the control group and the eplerenone group, at a significance level of 0.05, 128 carriers (64 in each group) are needed. To account for 10–15% loss to follow-up during the study, we aimed to include 150 subjects.

Randomisation and blinding

Central randomisation was conducted by the Trial Coordination Center of the University Medical Center Groningen (www.tcc.umcg.nl). Randomisation was stratified according to participating centres to ensure a similar sample distribution between the two test groups. According to the PROBE design, randomisation is blinded to the CMR core lab in the UMCG for assessment of the CMR images, which are performed as previously described [9]. An independent endpoint adjudication committee assesses the other primary and secondary endpoints.

Study organisation and monitoring

This is an investigator-initiated study organised by the executive steering committee, which is based in the Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands. The executive steering committee is responsible for overall supervision of the study, policy decisions, protocol amendments, publications and presentations. An independent DSMB monitors the overall conduct of this study by receiving and reviewing reports of serious adverse events, reviewing periodic reports of safety data and establishing 'stopping rules' for the trial for safety reasons only.

Biomarkers

Venous blood samples from all participants are stored and analysed for levels of biomarkers of fibrosis [21] and for biomarkers of apoptosis, haemodynamic status and inflammation. We will investigate whether these biomarkers predict disease progression. In addition to the volume of blood needed to measure these biomarkers, additional blood (serum and plasma) is taken and stored to allow for additional analyses in the future (samples stored for a maximum of 15 years). The amount of blood taken per venipuncture is 20 ml (at the start of the study and after 3 years). Carriers were asked to give their written informed consent for these additional analyses at the start of the study.

Statistical analysis

After completion of the study, all eligible carriers who have been randomised to the treatment arm and received at least 1 dose of eplerenone will be used in the analyses of the primary and secondary efficacy endpoints, as well as in the safety analysis. Safety will be assessed by summarising the incidence and type of adverse events and the changes in laboratory parameters. The proportion of carriers experiencing serious adverse events and the proportion of carriers with noteworthy changes in laboratory parameters will be compared between treatment groups. The analysis of primary endpoints and secondary endpoints will be performed according to their assigned treatment group in accordance with the intention-to-treat principle. Additional analysis sets may be used in exploratory analyses. The number of subjects withdrawing from the study will be tabulated by their reasons for withdrawal and by treatment group. Potenzial biases due to withdrawal of subjects will be investigated. Baseline characteristics will be compared using chi-squared test (or Fisher's exact test if appropriate). If differences are found, caution will be exercised when interpreting the results of the analyses between groups and methods may be modified to adjust for this difference.

The primary outcome will be presented by Kaplan-Meier curves for the treatment group, followed by the stratified log-rank test using stratification variables. Multivariate analysis will also be used to compare the endpoints between the two groups, adjusting for other variables including sex, age and screening centre. For missing data, the last observations made will be used. Unless stated otherwise, all secondary analyses will be performed using the same subjects included in the primary analysis. Secondary variables will be analysed using an appropriate statistical test, depending on the nature of the variable. Changes in parameters over time in the different treatment groups will be analysed using repeated measurement analysis or techniques that evaluate the timing of endpoints, when appropriate. For all tests, a p-value < 0.05 is considered statistically significant. Statistical analysis will be performed in SPSS (IBM SPSS Inc., Chicago, IL, USA; newest version at moment of analysis).

Baseline results

In May 2014, the first participant was included into the study. Because of slow recruitment, in January 2018 it was decided to stop further inclusion of participants and complete the protocolled follow-up duration with the included cohort (N=84). At this point, it had become clear that it was not realistic to assume that enough participants would be included to
Table 4  Baseline characteristics: no statistical differences between eplerenone and control group

|                          | All          | Eplerenone group | Control group |
|--------------------------|--------------|------------------|---------------|
| Number, n                | 84           | 42               | 42            |
| Age at inclusion, years (SD) | 39.5 (±13.1) | 40.2 (±13.0)     | 38.8 (±13.4)  |
| Male sex, n (%)          | 37 (44)      | 18 (43)          | 19 (45)       |
| Body mass index, kg/m² (SD) | 25.7 (±4.8)  | 26.5 (±5.6)      | 24.9 (±3.6)   |
| Systolic blood pressure, mm Hg (SD) | 124 (±16)   | 128 (±17)        | 121 (±13)     |
| Diastolic blood pressure, mm Hg (SD) | 74 (±11)    | 75 (±10)         | 74 (±11)      |
| ECG repolarisation abnormalities, n (%) | 18 (21)     | 13 (31)          | 5 (12)        |
| VPC, n (range)           | 8 (0–1861)   | 8 (0–1486)       | 12 (0–1861)   |
| LVEDV, ml (SD)           | 157 (±28)    | 160 (±23)        | 154 (±34)     |
| LVEF, % (SD)             | 60 (±0.04)   | 60 (±0.04)       | 59 (±0.05)    |
| LV-LGE, n (%)            | 14 (18)      | 9 (22)           | 5 (13)        |
| RVEDV, ml (SD)           | 178 (±34)    | 179 (±27)        | 176 (±42)     |
| RVEF, % (SD)             | 52 (±0.04)   | 52 (±0.04)       | 51 (±0.04)    |

SD standard deviation, ECG electrocardiogram, VPC ventricular premature complexes, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LV-LGE left ventricular late gadolinium enhancement, RVEDV right ventricular end-diastolic volume, RVEF right ventricular ejection fraction

reach the originally defined composite primary endpoint (Tab. 3). Instead of a composite dichotomous endpoint, i.e. using the pre-specified cut-off values, individual components of the primary endpoint will now be analysed on a continuous scale to investigate possible significant differences. The statistical analysis plan was amended accordingly, and the decision to amend the study design, i.e. to stop inclusion of participants and to continue with the included cohort, was supported by the DSMB and the medical ethics committee. The primary objective remains showing that eplerenone retards disease progression. The majority of participants have now finished the study and the remaining participants are expected to finish in 2021.

An overview of the baseline characteristics of the 84 participants is provided in Tab. 4. By design, at baseline, all participants were in NYHA class I and had an LVEF >45% and less than 2500 ventricular premature complexes (VPCs) during 24-hour Holter monitoring. Mean LVEF was 60% (±0.04). The median number of VPCs was 8 (0-1861). Baseline CMR scans were obtained for all 84 participants, but image quality was insufficient to perform adequate analyses in six cases. In the remaining 78 cases, as many as 14 cases (18%) showed LGE, mainly in the inferolateral left ventricular wall, suggestive of myocardial fibrosis. The six cases with insufficient image quality will be included for analysis of the other endpoints. An illustrative example is shown in Fig. 2. There were no statistically significant differences between the two groups in any of the baseline characteristics.

Discussion

The PLN p.Arg14del founder mutation causes DCM and ACM and is associated with an increased risk of malignant ventricular arrhythmia and heart failure [1, 8, 9]. Although DCM and ACM are considered separate entities by both the American Heart Association [22] and the European Society of Cardiology [23], they do have overlapping clinical features [24–26]. This is particularly true in PLN p.Arg14del cardiomyopathy, where we find significant clinical overlap [1].

The multicentre prospective randomised clinical iPHORECAST study aims to show that preventive treatment (eplerenone) can prevent or delay disease onset in presymptomatic PLN p.Arg14del carriers. Given eplerenone’s potent antifibrotic effects, we anticipate it may retard disease progression. Eplerenone has been shown to be well tolerated with minimal side-effects, even in advanced heart failure patients. The most significant side-effect is hyperkalaemia, which mainly occurs in combination with other potassium-sparing drugs and/or renal impairment. The presymptomatic subjects in the present study,
who all have normal kidney function are at very low risk for these side-effects. By using strict inclusion and exclusion criteria and follow-up monitoring, we are convinced that the use of eplerenone in the present study is safe.

The primary objective of this study is to assess the effect of eplerenone on disease onset and progression. To comply with daily clinical practice and demonstrate overall disease progression, a composite endpoint of CMR parameters (CMR volumes, systolic function and fibrosis), electrocardiographic parameters (QRS voltage, ventricular ectopy), signs and/or symptoms related to DCM and ACM, and cardiovascular death is adopted as the primary endpoint. Serum markers of fibrosis, apoptosis, haemodynamic status and inflammation are measured to investigate whether they can predict disease progression. Of note, as discussed in the baseline results, the actual number of participants was lower than projected. As a result, we will now perform an adapted assessment of the primary endpoint but are hopeful that meaningful results will be obtained. As to their clinical characteristics, the participants are a good reflection of clinical practice; indeed, many of these presymptomatic PLN p.Arg14del carriers already have subtle signs of disease, including repolarisation abnormalities of the ECG and frequent VPCs. Moreover, LGE on CMR, indicative of fibrosis, was observed in as many as 18% of the participants at the start of the study thereby supporting the rationale to study the effect of eplerenone.

In conclusion, iPHORECAST is a multicentre, randomised, controlled trial, designed to examine whether treatment with eplerenone in presymptomatic PLN p.Arg14del carriers can prevent or delay disease onset.

Acknowledgements We thank Kate McIntyre for editing the manuscript.

Funding This work was financially supported by the Netherlands Cardiovascular Research Initiative, an initiative supported by the Dutch Heart Foundation (The Hague, Netherlands): PREDICT 1 (CVON2012-10) and 2 (CVON 2018-30), DOSIS (CVON 2014-40) and eDETECT (CVON 2015-30). Furthermore, this study was supported by a grant (836011002) from ZonMW and the Leduq Foundation (CURE-PLAN). Eplerenone was provided by Pfizer. W.P.T.R. is supported by the Dutch Heart Foundation (Young Talent Program CVON PREDICT) and the Leduq Foundation (Postdoctoral Fellowship CURE-PLAN); Netherlands Heart Institute. B.D.W. is supported by the Netherlands Organisation for Scientific Research (NWO VENI grant 016.176.147) and the Netherlands Heart Foundation Senior Clinical Scientist Grant (2019T064). H.L.T. has received funding from the European Union’s Horizon 2020 research and innovation programme under acronym ESCAPE-NET, registered under grant agreement No 733381. FWA. is supported by UCL Hospitals NIHR Biomedical Research Centre.

Conflict of interest W.P. te Rijdt, E.T. Hoornjte, R. de Brouwer, A. Oomen, A. Amin, J.F. van der Heijden, J.C. Karper, B.D. Westenbrink, H.H.W. Stilljé, A.S.J.M. te Kiele, A.C.P. Wiesfeld, I.C. van Gelder, T.P. Willems, P.A. van der Zwaag, J.P. van Tintel, J.H. Hillegel, H.L. Tan, D.J. van Veldhuisen, E.W. Asselbergs, R.A. de Boer, A.A.M. Wilde and M.P. van den Berg declare that they have no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. van der Zwaag PA, van Rijsingen IA, Asimaki A, et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur J Heart Fail. 2012;14:1199–207.
2. van der Zwaag PA, Cox MG, van der Werf C, et al. Recurrent and founder mutations in the Netherlands: plakophilin-2 p.Arg79X mutation causing arrhythmogenic right ventricular cardiomyopathy/dysplasia. Neth Heart J. 2010;18:583–91.
3. van Rijsingen IA, van der Zwaag PA, Groeneveld JA, et al. Outcome in phospholamban R14del carriers: results of a large multicentre cohort study. Circ Cardiovasc Genet. 2014;7:455–65.
4. Milano A, Blom MT, Lapper EM, et al. Sudden cardiac arrest and rare genetic variants in the community. Circ Cardiovasc Genet. 2016;9:147–53.
5. Hof JE, van der Heijden JF, Kranias EG, et al. Prevalence and cardiac phenotype of patients with a phospholamban mutation. Neth Heart J. 2019;27:64–9.
6. Haghigi K, Kolokathis F, Gramolini AO, et al. Mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc Nat Acad Sci U S A. 2006;103:1388–93.
7. Eijgenraam TR, Boukens BJ, Boogerd CJ, et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. Sci Rep. 2020;10:9819.
8. Posch MG, Perrot A, Geier C, et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm. 2009;6:480–6.
9. Te Rijdt WP, Ten Sande JN, Gorter TM, et al. Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. Eur Heart J Cardiovasc Imaging. 2018;20:92–100.
10. Chai W, Danser AH. Why are mineralocorticoid receptor antagonists cardioprotective? Naunyn Schmiedebers Arch Pharmacol. 2006;374:153–62.
11. Iraji W, Rossignol P, Angioli M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart
Advertisement placed here.
Advertisement placed here.
Advertisement placed here.
Advertisement placed here.
11. Zannad F, Rossignol P, Iraqi W. Extracellular matrix fibrotic markers in heart failure. Heart Fail Rev. 2010;15:319–29.
12. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113:1807–16.
13. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29:270–6.
14. Maron BJ, Towbin JA, Thiene G, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512–20.
15. Sen-Chowdhry S, Syrris P, Ward D, et al. Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression. Circulation. 2007;115:1710–20.
16. Marcus FL, Zareba W, Calkins H, et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J. 2010;31:806–14.
17. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol. 2003;4:566–77.